Evidence map›Paper›PMID 34345601›Full record

ArticleJournal of advanced pharmaceutical technology & research

Martha Ervina, Mohammad Rizki Fadhil Pratama, Hadi Poerwono, Juni Ekowati, Retno Widyowati, Katsuyoshi Matsunami, Sukardiman

Open access · goldAbstract read
In one paragraph

Article in Journal of advanced pharmaceutical technology & research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Chemical profiling andFrontiers in nutrition · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Journal of advanced pharmaceutical technology & research
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Martha ErvinaDoctoral Program of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Palangka Raya, Indonesia.
Mohammad Rizki Fadhil PratamaDoctoral Program of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Palangka Raya, Indonesia.
Hadi PoerwonoDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Indonesia.
Juni EkowatiDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Indonesia.
Retno WidyowatiDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Indonesia.
Katsuyoshi MatsunamiDepartment of Pharmacognosy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Higashihiroshima, Japan.
SukardimanDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Indonesia.
Airlangga University · IDHiroshima University · JPUniversitas Katolik Widya Mandala Surabaya · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The estrogen hormone dependent accounts for a major cause in the incidence of women breast cancer. Thus, their receptor, especially the estrogen receptor α (ER-α), is becoming a target in endocrine treatment. These ligand-inducible nuclear functions are regulated by an array of phytochemical and synthetic compounds, such as 17 β-estradiol and tamoxifen (4-hydroxytamoxifen [4OHT]). The Chinaberry (

Indexed as

Estrogen receptor αflavonoidslimonoidsMelia azedarachsteroids

Identifiers

PMID34345601
PMCPMC8300330
OpenAlexW3185470627

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.